Timing of concurrent highly active antiretroviral therapy (HAART) in adults with tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 302s Year: 2006
Impact of HIV status, CD4 count and antiretroviral treatment on tuberculosis treatment outcomes in a low-burden country Source: International Congress 2017 – TB: co-morbidities and outcome Year: 2017
Bronchoscopy yield in HIV positive patients, ten years on from the introduction of highly active anti-retroviral therapy Source: Annual Congress 2009 - Aetiology and diagnosis of lower respiratory tract infections Year: 2009
Tuberculosis in HIV-infected persons in the context of wide availability of highly active antiretroviral therapy Source: Eur Respir J 2004; 24: 11-17 Year: 2004
The treatment of tuberculosis and application of HAART (highly active anti retroviral treatment) in HIV positive patients Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem Year: 2005
Impact of adverse drug reactions on treatment interruption in TB patients with and without HIV coinfection Source: ISSN=ISSN 1810-6838, ISBN=, page=190 Year: 2006
The role of adherence in tuberculosis HIV-positive patients treated in ambulatory regimen Source: Eur Respir J 2003; 21: 785-788 Year: 2003
Screening and monitoring of TB infection in rheumatological patients on biologics therapy Source: Virtual Congress 2021 – Epidemiological aspects of tuberculosis Year: 2021
Improvement of HIV-related pulmonary hypertension after the introduction of an antiretroviral therapy Source: Eur Respir J 2009; 34: 277-278 Year: 2009
Early initiation of antiretroviral therapy results in decreased morbidity and mortality among patients with advanced HIV disease Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2008
Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Current antiretroviral therapy Source: Eur Respir Monogr 2014; 66: 12-25 Year: 2014
Tolerability of rifapentine-based regimens in latent tuberculosis infection treatment in the elderly Source: Eur Respir J, 53 (3) 1802396; 10.1183/13993003.02396-2018 Year: 2019
Immunologic recovery in HIV/TB co-infected patients after anti-TB treatment Source: Annual Congress 2009 - Tuberculosis and HIV co-infection Year: 2009
HIV co-infection excludes many drug-resistant tuberculosis patients from clinical trials with novel antituberculosis drugs Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Effect of HIV counseling and testing program on patients‘ adherence of isoniazid preventive therapy (IPT) Source: Eur Respir J 2005; 26: Suppl. 49, 455s Year: 2005
Outcomes of treatment of latent tuberculosis infection in children with two different regimens Source: Eur Respir J 2006; 28: Suppl. 50, 487s Year: 2006
A choice of regimen improves completion for patients with latent TB infection Source: Breathe 2008; 4: 366 Year: 2008
Long term plasma rifampicin (R) concentrations in AIDS patients with tuberculosis (TB) under HAART therapy Source: Eur Respir J 2003; 22: Suppl. 45, 40s Year: 2003
Evaluation of empirical treatment of tuberculosis (TB) before and after the implementation of highly active antiretroviral therapy (HAART) in a teaching hospital (HUCFF/UFRJ), reference for acquired immunodeficiency syndrome (AIDS), in Rio de Janeiro, Source: Eur Respir J 2001; 18: Suppl. 33, 340s Year: 2001